Market Data 
Markets
Replies to post #199505 on Biotech Values
03/04/16 9:47 AM
Novo Nordisk today announced the top-line results from the LEADER trial, which investigated the cardiovascular safety of Victoza over a period of up to 5 years in more than 9,000 adults with type 2 diabetes at high risk of major adverse cardiovascular events.
The trial compared the addition of either Victoza or placebo to standard of care and met the primary endpoint of showing non-inferiority as well as demonstrating superiority, with a statistically significant reduction in cardiovascular risk. The primary endpoint of the study was defined as the composite outcome of the first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. The superior reduction of major adverse cardiovascular events demonstrated by Victoza was derived from all three components of the endpoint.
AI
